A trial was conducted in which ticagrelor was compared to clopidogrel (the PLATO trial).20 A total of 10,285 patients with acute coronary syndrome were genotyped for CYP2C19 and ABCB1 and then randomized to receive ticagrelor or clopidogrel. Here, CYP2C19 is linked to acute coronary syndrome.